Aug 12, 2020
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
Jun 16, 2020
IDEAYA and GSK Announce a Broad Partnership in Synthetic Lethality, an Emerging Field in Precision Medicine Oncology
Jun 08, 2020
IDEAYA Announces Nomination of Development Candidate, IDE397, for MAT2A Synthetic Lethality Program Targeting MTAP-Deletion Patient Population
May 15, 2020
IDEAYA Biosciences Announces AACR Abstracts for IDE196 Targeting GNAQ/11 Tumors and Preclinical MAT2A Synthetic Lethality Program
May 12, 2020
IDEAYA Biosciences, Inc. Reports First Quarter 2020 Financial Results and Provides Business Update
Apr 21, 2020
IDEAYA Biosciences Announces Addition of Julie Patel as Vice President, Human Resources, Enhancing its Leadership Team
Mar 24, 2020
IDEAYA Biosciences, Inc. Reports Fourth Quarter 2019 Financial Results and Provides Business Update
Mar 11, 2020
IDEAYA Biosciences and Cancer Research UK Announce Expanded Research Collaboration for PARG, a DDR-Based Synthetic Lethality Target, Evaluating DNA Replication Vulnerabilities
Jan 15, 2020
IDEAYA Biosciences Announces Synthetic Lethality Research Highlights and Target Milestones for 2020
Jan 10, 2020
IDEAYA Biosciences and Boston Children's Hospital Collaborate on Preclinical Evaluation of IDE196 for Sturge Weber Syndrome - a Rare Disease Associated with Genetic Mutation of GNAQ
Dec 09, 2019
IDE196 Program Updates: Targeting Initiation of Potentially Registration-Enabling Phase 2 Single-Arm Monotherapy Trial in MUM and Introduction of Tablet Formulation in Q1 2020
Nov 13, 2019
IDEAYA Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
Nov 06, 2019
Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor
Sep 30, 2019
Synthetic Lethality-based Drugs and Targets Market, 2030
Aug 16, 2019
With Over USD 4 Billion in Capital Investment, the Synthetic Lethality-based Drugs Market is Poised to Witness a Rapid Growth, Claims Roots Analysis
Aug 12, 2019
IDEAYA Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
Jul 11, 2019
IDEAYA Biosciences Announces First Patient Dosing of PKC inhibitor IDE196 in Phase 1/2 Tissue-Type Agnostic Basket Trial for Solid Tumors Harboring GNAQ or GNA11 Mutations
Mar 31, 2019
Cyteir Therapeutics Announces New Data Demonstrating Lead Compound CYT-0851 is Active Against Lymphomas and Solid Tumors, Synergistic with PARP Inhibitors
May 10, 2018
Sierra Oncology Reports First Quarter Results
Apr 17, 2018
Sierra Late-Breaking Data Demonstrating SRA737 Preclinical Activity with PARPi to be Presented at the AACR 2018 Annual Meeting